Elizabeth A. Winzeler

De novo minibinders targeting RH5 achieve nanomolar inhibition of blood-stage malaria replication

This paper designs de novo minibinders that inhibit blood-stage malaria replication with nanomolar potency by targeting the RH5-basigin interaction.

Shared Binding Site but Divergent Resistance Profiles Uncover Novel Resistance Mechanisms in Plasmodium HSP90 Inhibitors

This study identifies divergent resistance mechanisms in Plasmodium HSP90 inhibitors despite shared binding sites, showing that enhanced binding can paradoxically correlate with resistance.

AI-Accelerated Structure Elucidation of Boavistamides A-C, Cyclic Depsipeptides from a Marine Filamentous Cyanobacterium Collected in Cabo Verde

The paper identifies three new cyclic depsipeptides from a marine cyanobacterium using AI tools and metabolomics, showing their antiplasmodial activity and structural diversity.

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of PfArk1 and Hemozoin Formation

This study shows that CHIR-124, a human Chk1 inhibitor, is active against Plasmodium falciparum through dual inhibition of PfArk1 and hemozoin formation, suggesting polypharmacology as a strategy for antimalarial drugs.

Duplication of superoxide dismutase and a mutation in aquaglyceroporin mediates the sensitivity of Plasmodium falciparum to cryptosporin, a natural product derived from Acaromyces ingoldii

This study identifies a mutation in PfAQP and duplication of superoxide dismutase genes as mechanisms of resistance to cryptosporin in Plasmodium falciparum.

Structure and functional diversity of antibodies targeting the P. falciparum circumsporozoite protein C-terminal domain

This study characterizes the structure and function of antibodies targeting the conserved β-epitope region of PfCSP, showing how they achieve strain-transcending recognition and enhance Fc-mediated immune responses.

Single-cell analysis of Plasmodium falciparum transcripts after drug perturbation identifies feedback regulation as well as increased transmission potential

This study uses scRNA-seq to analyze Plasmodium falciparum transcript responses to three drugs, revealing distinct transcriptional profiles and feedback regulation.

Mechanistic Insights into Dual-Active Liver and Blood-Stage Antiplasmodials

This paper identifies targets of dual-active antimalarials by evolving resistance to nine compounds and validates them using CRISPR and molecular docking.

Targeting Aurora kinases as essential cell cycle regulators to deliver multi-stage antimalarials against Plasmodium falciparum

The paper identifies PfArk1 as a key target for antimalarial drugs by showing that inhibiting it disrupts parasite mitosis and nuclear division.

A novel chemogenomic screening platform for scalable antimalarial drug target identification

This paper develops a chemogenomic platform using Plasmodium berghei artificial chromosomes to identify antimalarial drug targets through barcode sequencing and validation in Plasmodium falciparum.

Target deconvolution using in vitro evolution in haploid human cells

The paper uses in vitro evolution in haploid human cells to identify drug resistance mechanisms and validates them through gene expression experiments.

CACTI: An in-silico drug-target prediction tool through the integration of chemogenomic data and clustering analysis

CACTI integrates chemogenomic data and clustering analysis to predict drug targets and annotate compound synonyms, enhancing the evaluation of chemical libraries.

Defining the Yeast Resistome through in vitro Evolution and Whole Genome Sequencing

The paper identifies genetic determinants of chemical resistance in yeast using in vitro evolution and whole genome sequencing, revealing key transcription factors involved in drug resistance.

Validation of the protein kinase PfCLK3 as a multi-stage cross species malarial drug target

This study identifies PfCLK3 as a druggable target for malaria by showing its essential role in multiple parasite life stages across species.

Dual RNAseq shows the human mucosal immunity protein, MUC13, is a hallmark of Plasmodium exoerythrocytic infection

The paper identifies MUC13 as upregulated in Plasmodium exoerythrocytic hepatic-stage infection and shows it can be used to identify anti-parasite compounds.

Mapping The Malaria Parasite Drug-Able Genome Using In Vitro Evolution And Chemogenomics

Whole genome sequencing reveals how Plasmodium falciparum evolves resistance to diverse compounds and identifies new antimalarial drug targets.